AR109264A1 - Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 - Google Patents
Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123Info
- Publication number
- AR109264A1 AR109264A1 ARP170101993A ARP170101993A AR109264A1 AR 109264 A1 AR109264 A1 AR 109264A1 AR P170101993 A ARP170101993 A AR P170101993A AR P170101993 A ARP170101993 A AR P170101993A AR 109264 A1 AR109264 A1 AR 109264A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- sequence
- sequence seq
- polypeptide
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
También se refiere a composiciones farmacéuticas que comprenden dicha proteína de unión semejante a anticuerpo y al uso de dichas composiciones farmacéuticas y proteína de unión semejante a anticuerpo para tratar cáncer. Se refiere además a ácidos nucleicos aislados, vectores y células huésped que comprenden una secuencia que codifica dicha proteína de unión semejante a anticuerpo. Reivindicación 1: Una proteína de unión semejante a anticuerpo que se une específicamente a CD3e humano y CD123 humano que comprende dos cadenas de polipéptido que forman dos sitios de unión a antígeno, en el que una cadena de polipéptido tiene una estructura representada por la fórmula [1]: VD₁-L₁-VD₂-L₂-CL-L₅-Fᶜ₂ [1] y una cadena de polipéptido tiene una estructura representada por la fórmula [2]: VD₃-L₃-VD₄-L₄-CH₁-Fᶜ [2] en el que: a) el polipéptido de fórmula [1] consiste en: (i) la secuencia de aminoácidos SEQ ID Nº 71 que comprende VD₁ de secuencia SEQ ID Nº 54, L₁ de secuencia SEQ ID Nº 56, VD₂ de secuencia SEQ ID Nº 10, L₂ de secuencia SEQ ID Nº 56, CL de secuencia SEQ ID Nº 18, L₅ consiste en 0 aminoácidos, y Fᶜ₂ consiste en la secuencia SEQ ID Nº 70, en el que X¹ es Y, X² es S, X³ es T, X⁴ es L, X⁵ es Y y X⁶ es H y X⁷ es Y, o en el que X¹ es Y, X² es C, X³ es W, X⁴ es L, X⁵ es Y y X⁶ es H y X⁷ es Y, o en el que X¹ es Y, X² es C, X³ es W, X⁴ es L, X⁵ es Y y X⁶ es R y X⁷, es F, o (ii) una secuencia al menos 85% idéntica a SEQ ID Nº 71 en la que: las 3 CDR de secuencias SEQ ID Nº 48, WAS y SEQ ID Nº 49 de VD₁ de secuencia SEQ ID Nº 54 están inalteradas, y las 3 CDR de secuencias SEQ ID Nº 11, KVS y SEQ ID Nº 8 de VD₂ de secuencia SEQ ID Nº 10 están inalteradas, y los aminoácidos X¹, X², X³, X⁴, X⁵, X⁶ y X⁷ en SEQ ID Nº 71 son como se ha definido anteriormente en a)(i); b) dicho polipéptido de fórmula [2] consiste en: (i) la secuencia de aminoácidos SEQ ID Nº 67 que comprende VD₃ de secuencia SEQ ID Nº 9, L₃ que consiste en 0 aminoácidos, VD₄ de secuencia SEQ ID Nº 52, L₄ que consiste en 0 aminoácidos, CH₁ de secuencia SEQ ID Nº 19, y Fᶜ consiste en la secuencia SEQ ID Nº 68, en la que X¹ es Y o C, X² es S o C, X³ es T, S o W, X⁴ es A o L, X⁵ es V o Y, X⁶ es H o R, y X⁷ es Y o F, o (ii) una secuencia al menos 85% idéntica a SEQ ID Nº 67 en la que: las 3 CDR de secuencias SEQ ID Nº 50, SEQ ID Nº 53, y SEQ ID Nº 51 de VD₄ de secuencia SEQ ID Nº 52 están inalteradas, y las 3 CDR de secuencias SEQ ID Nº 5, SEQ ID Nº 6, SEQ ID Nº 7 de VD₃ de secuencia SEQ ID Nº 9 están inalteradas, y los aminoácidos X¹, X², X³, X⁴, X⁵, X⁶ y X⁷ de SEQ ID Nº 67 son como se define anteriormente en b)(i), y en el que el polipéptido formula [1] y el polipéptido de fórmula [2] forman una pareja cadena ligera-cadena pesada entrecruzada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305923 | 2016-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109264A1 true AR109264A1 (es) | 2018-11-14 |
Family
ID=56507555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101993A AR109264A1 (es) | 2016-07-18 | 2017-07-17 | Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20190241657A1 (es) |
| EP (1) | EP3484924A1 (es) |
| JP (2) | JP7071329B2 (es) |
| KR (1) | KR20190028771A (es) |
| CN (1) | CN109715665A (es) |
| AR (1) | AR109264A1 (es) |
| AU (1) | AU2017299125A1 (es) |
| BR (1) | BR112019000770A2 (es) |
| CA (1) | CA3030943A1 (es) |
| CL (1) | CL2019000119A1 (es) |
| CO (1) | CO2019001367A2 (es) |
| CR (1) | CR20190072A (es) |
| DO (1) | DOP2019000011A (es) |
| EA (1) | EA201990321A1 (es) |
| EC (1) | ECSP19011185A (es) |
| IL (1) | IL264248A (es) |
| MA (1) | MA45680A (es) |
| MX (1) | MX2019000844A (es) |
| PE (1) | PE20190514A1 (es) |
| PH (1) | PH12019500122A1 (es) |
| SG (1) | SG11201900400QA (es) |
| TN (1) | TN2019000015A1 (es) |
| TW (1) | TWI790206B (es) |
| WO (1) | WO2018015340A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3247725T (pt) | 2015-01-23 | 2020-10-07 | Sanofi Sa | Anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam de forma biespecífica a cd3 e/ou a cd123 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| MX2021004868A (es) * | 2018-10-30 | 2021-09-08 | Macrogenics Inc | Diacuerpos cd123 x cd3 biespecificos para el tratamiento de neoplasias hematologicas. |
| CN113874400A (zh) * | 2019-03-11 | 2021-12-31 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
| CN111171155B (zh) * | 2020-02-05 | 2021-02-19 | 北京智仁美博生物科技有限公司 | 抗cd3和cd123双特异性抗体及其用途 |
| TW202200619A (zh) * | 2020-03-17 | 2022-01-01 | 美商西雅圖免疫公司 | 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法 |
| US11965024B2 (en) | 2020-09-11 | 2024-04-23 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
| JP2024506831A (ja) | 2021-01-28 | 2024-02-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | サイトカイン放出症候群を治療するための組成物及び方法 |
| CN113368232B (zh) * | 2021-06-02 | 2022-08-26 | 上海交通大学 | 多特异性抗原结合蛋白及其应用 |
| WO2023012367A1 (en) * | 2021-08-06 | 2023-02-09 | Universität Basel | Discernible cell surface protein variants for use in cell therapy |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| US20240277844A1 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| AU6642390A (en) | 1989-10-27 | 1991-05-31 | Arch Development Corporation | Methods and compositions for promoting immunopotentiation |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| JP3298879B2 (ja) | 1990-12-20 | 2002-07-08 | イグジス，インコーポレイテッド | 結合タンパク質の最適化 |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AU690474B2 (en) | 1995-09-11 | 1998-04-23 | Kyowa Hakko Kirin Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| WO1997024373A1 (en) | 1995-12-29 | 1997-07-10 | Medvet Science Pty. Limited | Monoclonal antibody antagonists to haemopoietic growth factors |
| DE19721700C1 (de) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
| NZ507381A (en) | 1998-04-21 | 2003-12-19 | Micromet Ag | CD19xCD3 specific polypeptides and uses thereof |
| CA2895884C (en) | 2000-03-06 | 2019-04-23 | University Of Kentucky Research Foundation | A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells |
| SG10201407388XA (en) | 2007-08-29 | 2015-01-29 | Sanofi Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| AU2009299791B2 (en) * | 2008-10-01 | 2016-02-25 | Amgen Research (Munich) Gmbh | Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody |
| TWI838039B (zh) | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| PE20141521A1 (es) | 2011-08-23 | 2014-10-25 | Roche Glycart Ag | Moleculas biespecificas de union a antigeno activadoras de celulas t |
| ES2924722T3 (es) * | 2012-05-18 | 2022-10-10 | Aptevo Res & Development Llc | Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3 |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| MX2016006741A (es) * | 2013-12-10 | 2016-08-12 | Hoffmann La Roche | Uso del dominio de union de una subunidad de una estructura de multiples subunidades para la liberacion dirigida de entidades farmaceuticamente activas a la estructura de multiples subunidades. |
| HUE048791T2 (hu) * | 2014-09-05 | 2020-09-28 | Janssen Pharmaceutica Nv | CD123 kötõszerek és alkalmazásaik |
| CN110894240B (zh) * | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| PT3247725T (pt) * | 2015-01-23 | 2020-10-07 | Sanofi Sa | Anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam de forma biespecífica a cd3 e/ou a cd123 |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
-
2017
- 2017-07-14 TW TW106123588A patent/TWI790206B/zh active
- 2017-07-17 AR ARP170101993A patent/AR109264A1/es unknown
- 2017-07-17 EA EA201990321A patent/EA201990321A1/ru unknown
- 2017-07-17 JP JP2019502257A patent/JP7071329B2/ja active Active
- 2017-07-17 MX MX2019000844A patent/MX2019000844A/es unknown
- 2017-07-17 BR BR112019000770A patent/BR112019000770A2/pt not_active IP Right Cessation
- 2017-07-17 EP EP17749380.6A patent/EP3484924A1/en not_active Withdrawn
- 2017-07-17 US US16/318,599 patent/US20190241657A1/en not_active Abandoned
- 2017-07-17 CR CR20190072A patent/CR20190072A/es unknown
- 2017-07-17 CA CA3030943A patent/CA3030943A1/en active Pending
- 2017-07-17 MA MA045680A patent/MA45680A/fr unknown
- 2017-07-17 CN CN201780056945.7A patent/CN109715665A/zh active Pending
- 2017-07-17 WO PCT/EP2017/068020 patent/WO2018015340A1/en unknown
- 2017-07-17 SG SG11201900400QA patent/SG11201900400QA/en unknown
- 2017-07-17 PE PE2019000065A patent/PE20190514A1/es not_active Application Discontinuation
- 2017-07-17 KR KR1020197004345A patent/KR20190028771A/ko not_active Application Discontinuation
- 2017-07-17 TN TNP/2019/000015A patent/TN2019000015A1/en unknown
- 2017-07-17 AU AU2017299125A patent/AU2017299125A1/en not_active Abandoned
-
2019
- 2019-01-15 IL IL264248A patent/IL264248A/en unknown
- 2019-01-16 CL CL2019000119A patent/CL2019000119A1/es unknown
- 2019-01-16 PH PH12019500122A patent/PH12019500122A1/en unknown
- 2019-01-16 DO DO2019000011A patent/DOP2019000011A/es unknown
- 2019-02-15 CO CONC2019/0001367A patent/CO2019001367A2/es unknown
- 2019-02-15 EC ECSENADI201911185A patent/ECSP19011185A/es unknown
-
2022
- 2022-05-02 JP JP2022075664A patent/JP2022105138A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201900400QA (en) | 2019-02-27 |
| CR20190072A (es) | 2019-06-25 |
| EA201990321A1 (ru) | 2019-06-28 |
| IL264248A (en) | 2019-02-28 |
| WO2018015340A1 (en) | 2018-01-25 |
| MA45680A (fr) | 2019-05-22 |
| MX2019000844A (es) | 2019-07-04 |
| US20190241657A1 (en) | 2019-08-08 |
| PH12019500122A1 (en) | 2019-04-15 |
| AU2017299125A1 (en) | 2019-03-07 |
| ECSP19011185A (es) | 2019-02-28 |
| PE20190514A1 (es) | 2019-04-10 |
| KR20190028771A (ko) | 2019-03-19 |
| CL2019000119A1 (es) | 2019-06-14 |
| CO2019001367A2 (es) | 2019-02-19 |
| BR112019000770A2 (pt) | 2019-07-02 |
| CN109715665A (zh) | 2019-05-03 |
| JP2019531701A (ja) | 2019-11-07 |
| DOP2019000011A (es) | 2019-05-15 |
| TN2019000015A1 (en) | 2020-07-15 |
| JP2022105138A (ja) | 2022-07-12 |
| JP7071329B2 (ja) | 2022-05-18 |
| CA3030943A1 (en) | 2018-01-25 |
| TWI790206B (zh) | 2023-01-21 |
| EP3484924A1 (en) | 2019-05-22 |
| TW201811830A (zh) | 2018-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109264A1 (es) | Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
| CO2018012415A2 (es) | Proteínas de unión específica y usos de las mismas | |
| MX2022009306A (es) | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. | |
| PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
| AR117727A1 (es) | Anticuerpos que se unen a cd3 | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| AR095614A1 (es) | Anticuerpos heterodiméricos biespecíficos | |
| AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
| EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
| PH12020551907A1 (en) | Antagonizing cd73 antibody | |
| MX2019005116A (es) | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). | |
| EA201892561A1 (ru) | Гибридные белки gdf15 и их применение | |
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| AR108034A1 (es) | Moléculas de unión a ror1, y métodos de uso de las mismas | |
| EA201992755A1 (ru) | Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4) | |
| EA201490020A1 (ru) | Растворимые белки для применения в качестве терапевтических средств | |
| CO6761352A2 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| AR101753A1 (es) | COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO | |
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
| AR108779A1 (es) | Anticuerpos | |
| EA202190267A1 (ru) | Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |